Skip to content

Author

S. Yaylacı

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Dexmedetomidine May Delay Intubation in Patients With Severe COVID-19

Aim/Objective: Dexmedetomidine (DEX), a highly selective α2-adrenoceptor agonist, has sedative, analgesic, anxiolytic, and immunomodulatory properties that may provide benefits in critically ill patients with COVID-19. This study aimed to evaluate the effect of DEX on clinical outcomes in patients with severe COVID-19...

Kubilay Işsever, A. Genç, A. C. Genç et al. · 0 citations
Open access Aug 2026

Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye.

The role of FIB-4 as a simple, cost-effective tool for integrated cardio-hepato-renal risk stratification is supported, and impaired kidney function in patients with MASLD beyond established cardiometabolic risk factors is independently associated with impaired kidney function in patients with MASLD.

H. Sumbul, A. Kırık, S. Yaylacı et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.